

A Phase I/IIa, First-in-Human, Multicenter, Monotherapy and Combination-Therapy with Nivolumab, Dose-Finding and Dose-Expansion Study of (212Pb)VMT01 Melanocortin-1-Receptor-Targeted, Image-Guided, Alpha-Particle Therapy in Subjects with Previously Treated Unresectable or Metastatic Melanoma (VMT01-T101)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- ages 18 or older - diagnosed with advanced melanoma that cannot be removed by surgery, has spread, or has returned - previously received at least one approved treatment for advanced melanoma and had the cancer worsen - see link to clinicaltrials.gov for complete inclusion criteria

Exclusion Criteria:

- have another active cancer - are pregnant or breastfeeding - have previously received systemic treatment with radioactive medicines - see link to clinicaltrials.gov for complete exclusion criteria

Conditions & Interventions

Interventions:

Drug: Nivolumab, Drug: [203Pb]VMT01, Drug: [212Pb]VMT01

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Cancer, Melanoma, Nivolumab

More Information

Description: This study is testing a radioactive treatment for adults with advanced melanoma that has spread, cannot be removed by surgery, or has gotten worse after prior treatment. We want to learn how safe the treatment is and how well it may work. By taking part, participants may help us learn whether this could become a useful treatment option for people with advanced melanoma.

Study Contact: Benjamin Manning - mann0233@umn.edu

Principal Investigator: Benjamin Manning

Phase: PHASE1

IRB Number: STUDY00025911

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.